Brief: Newamsterdam Pharma Completes Enrollment In Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia
24/04/2023 13:25
April 24 (Reuters) - NewAmsterdam Pharma Company NV
NAMS.O :
* NEWAMSTERDAM PHARMA COMPLETES ENROLLMENT IN PIVOTAL PHASE
3
BROOKLYN CLINICAL TRIAL EVALUATING OBICETRAPIB IN PATIENTS WITH
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
* NEWAMSTERDAM PHARMA COMPANY NV - TOPLINE RESULTS EXPECTED
IN 2H
2024
Source text for Eikon: ID:nGNX5j0P6y
Further company coverage: NAMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)